GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XSpray Pharma AB (STU:6XP) » Definitions » Price-to-Free-Cash-Flow

XSpray Pharma AB (STU:6XP) Price-to-Free-Cash-Flow : N/A (As of May. 22, 2025)


View and export this data going back to 2018. Start your Free Trial

What is XSpray Pharma AB Price-to-Free-Cash-Flow?

As of today (2025-05-22), XSpray Pharma AB's share price is €2.735. XSpray Pharma AB's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 was €-0.73. Hence, XSpray Pharma AB's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for XSpray Pharma AB's Price-to-Free-Cash-Flow or its related term are showing as below:

STU:6XP's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.09
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

XSpray Pharma AB's Free Cash Flow per Share for the three months ended in Mar. 2025 was €-0.20. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was €-0.73.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -2.00% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -3.20% per year.

During the past 10 years, XSpray Pharma AB's highest 3-Year average Free Cash Flow per Share Growth Rate was -2.00% per year. The lowest was -67.10% per year. And the median was -18.60% per year.


XSpray Pharma AB Price-to-Free-Cash-Flow Historical Data

The historical data trend for XSpray Pharma AB's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XSpray Pharma AB Price-to-Free-Cash-Flow Chart

XSpray Pharma AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

XSpray Pharma AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of XSpray Pharma AB's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, XSpray Pharma AB's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XSpray Pharma AB's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XSpray Pharma AB's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where XSpray Pharma AB's Price-to-Free-Cash-Flow falls into.


;
;

XSpray Pharma AB Price-to-Free-Cash-Flow Calculation

XSpray Pharma AB's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=2.735/-0.726
=N/A

XSpray Pharma AB's Share Price of today is €2.735.
XSpray Pharma AB's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.73.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

XSpray Pharma AB  (STU:6XP) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


XSpray Pharma AB Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of XSpray Pharma AB's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


XSpray Pharma AB Business Description

Traded in Other Exchanges
Address
Scheeles vag 2, Solna, SWE, SE-171 65
XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and other.

XSpray Pharma AB Headlines

No Headlines